Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of RGX-202-01 (Ompenaclid) , a Small Molecule Inhibitor of the Creatine Transporter SLC6a8, as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies With Select Expansion Cohorts

Next Previous
Trial Profile

A Phase 1 Study of RGX-202-01 (Ompenaclid) , a Small Molecule Inhibitor of the Creatine Transporter SLC6a8, as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies With Select Expansion Cohorts

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Ompenaclid (Primary)
  • Indications Adenocarcinoma; Biliary cancer; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Intestinal cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Inspirna

    • Most Recent Events

    • 24 Oct 2023 Results assessing safety, PK/PD and efficacy of ompenaclid + FOLFIRI/BEV in 2L mCRC patients ( as of 28Apr2023, 35 pts), presented at the 48th European Society for Medical Oncology Congress
    • 23 Oct 2023 According to an Inspirna media release, as of Sep 18, 2023, 50 patients in the dose escalation/expansion cohorts received either 2400mg twice daily (BID) of ompenaclid plus FOLFIRI/BEV (n = 27) or 3000mg BID ompenaclid plus FOLFIRI/BEV (n = 23). 39 patients were evaluable for RECIST 1.1 response if they completed at least one treatment cycle and had at least one follow-up on treatment scan.
    • 23 Oct 2023 Results presented in an Inspirna media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top